SynthesisCellular & molecular biology letters2026
Differentiation state affects PD-L1 expression in cutaneous melanoma: a systematic review.
Synthesis in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundProgrammed death ligand-1 (PD-L1) is a widely used biomarker for immunotherapy in melanoma. The expression of PD-L1 in melanoma cells is known to vary considerably among and within patients' tumor samples. Recent studies suggest that there may be a link between PD-L1 expression and the differentiation status of melanoma cells which is known to fluctuate in response to external stimuli and to be influenced by a multitude of regulators. Here, we systematically review which differentiation regulators affect PD-L1 expression in melanoma.
methodsA systematic review was performed on studies collected through PubMed, Scopus, and Web of Knowledge up until February 13
resultsOut of 496 identified articles, 57 studies met the inclusion criteria. A total of 16 differentiation regulators were significantly associated with PD-L1 expression in melanoma cells. Most studies (45/57) reported a single regulator, while 12/57 reported multiple. STAT3 appeared in 20/57 studies; all other regulators were reported in eight or fewer. PD-L1 expression was positively associated with all dedifferentiation-linked regulators (9/9). Among differentiation-linked regulators, 3/4 (MITF, SOX10, IRF4) showed contrasting associations depending on the PD-L1 expression mode and study. In total, 120 human and 10 mouse melanoma cell lines were used. The A375, SK-MEL-28, and B16 cell lines were used in 20, 18, and 28 studies, respectively, suggesting lineage bias. Most studies had unclear risk of bias regarding imprecision (82%) and model validity (70%).
conclusionsPD-L1 expression is commonly affected by differentiation regulators in melanoma cells, linking high PD-L1 expression to dedifferentiated cell states. The various regulators and inducible pathways that affect PD-L1 may in turn explain the heterogeneity observed in PD-L1 expression between and within patients with melanoma. Owing to the clinical significance of PD-L1 expression as a predictive biomarker for immunotherapy response, it is crucial to better understand the impact of various regulators on its expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.